Figure 5.

Kaplan–Meier survival plot of disease-free survival by pCR, MPR, TCR D50, PD1⁺CD8⁺ cells, CD3⁺ cells, CD8⁺ cells, and TMB. (A) pCR patients had a longer median disease-free survival (mDFS) than non-pCR patients (NR vs. 23.4 m, Log rank test, χ ² = 3.994, p = 0.041). (B) A longer mDFS was observed in patients with high TCR clonality than those with low TCR clonality (29.4 m vs. 13.4 m, Log rank test, χ ² = 6.660, p = 0.009). (C) A longer mDFS was observed in patients with high-level CD8⁺ cells than those with low-level CD8⁺ cell (NR vs. 19.2 m, Log rank test, χ ² = 7.182, p = 0.007). (D) A longer mDFS was observed in patients with high-level PD1⁺CD8⁺ cells than those with low level PD1⁺CD8⁺ cells (29.4 m vs. 14.4 m, Log rank test, χ ² = 3.852, p = 0.049). (E) mDFS was numerically but not statistically longer in patients with high-level CD3⁺ cells than those with low-level CD3⁺ cells (28.7 m vs. 21.3 m, χ ² = 1.192, p = 0.275). (F) Not statistically different mDFS was found between MPR patients and non-MPR patients (25.7 m vs. 23.4 m, Log rank test, χ ² = 0.810, p = 0.368). (G) Not statistically different mDFS was found between high TMB and low TMB patients (25.8 m vs. 18.0 m, Log rank test, χ ² = 0.272, p = 0.602).